ERY-974 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ERY-974’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ERY-974 is under development for the treatment of solid tumors including gastric and gastroesophageal junction carcinoma, squamous cell esophageal carcinomau and metastatic hepatocellular carcinoma. It is administered intravenously. The therapeutic candidate is a bi-specific monoclonal antibody which recognizes both CD3 and cancer cells expressing glypican3 (GPC3). It is a new molecular entity (NME). The drug candidate is developed based on engineering technology [TRAB].
Chugai Pharmaceutical overview
Chugai Pharmaceutical (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, manufacturing, commercialization, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
For a complete picture of ERY-974’s drug-specific PTSR and LoA scores, buy the report here.